As of 2026-03-16, the EV/EBITDA ratio of Esperion Therapeutics Inc (ESPR) is -41.54. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ESPR's latest enterprise value is 1,215.23 mil USD. ESPR's TTM EBITDA according to its financial statements is -29.25 mil USD. Dividing these 2 quantities gives us the above ESPR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.5x - 14.7x | 12.0x |
| Forward P/E multiples | 14.3x - 19.2x | 16.2x |
| Fair Price | (2.59) - (1.48) | (2.23) |
| Upside | -206.2% - -160.6% | -191.4% |
| Date | EV/EBITDA |
| 2026-03-13 | -41.54 |
| 2026-03-12 | -41.84 |
| 2026-03-11 | -43.04 |
| 2026-03-10 | -44.13 |
| 2026-03-09 | -47.51 |
| 2026-03-06 | -44.33 |
| 2026-03-05 | -44.83 |
| 2026-03-04 | -46.22 |
| 2026-03-03 | -46.22 |
| 2026-03-02 | -49.80 |
| 2026-02-27 | -50.59 |
| 2026-02-26 | -50.69 |
| 2026-02-25 | -50.39 |
| 2026-02-24 | -50.10 |
| 2026-02-23 | -50.49 |
| 2026-02-20 | -51.89 |
| 2026-02-19 | -52.28 |
| 2026-02-18 | -52.78 |
| 2026-02-17 | -52.58 |
| 2026-02-13 | -51.39 |
| 2026-02-12 | -51.09 |
| 2026-02-11 | -51.69 |
| 2026-02-10 | -50.99 |
| 2026-02-09 | -50.30 |
| 2026-02-06 | -51.09 |
| 2026-02-05 | -48.90 |
| 2026-02-04 | -51.29 |
| 2026-02-03 | -52.18 |
| 2026-02-02 | -52.09 |
| 2026-01-30 | -50.99 |
| 2026-01-29 | -52.58 |
| 2026-01-28 | -51.69 |
| 2026-01-27 | -51.29 |
| 2026-01-26 | -50.49 |
| 2026-01-23 | -48.51 |
| 2026-01-22 | -48.80 |
| 2026-01-21 | -46.91 |
| 2026-01-20 | -46.02 |
| 2026-01-16 | -47.51 |
| 2026-01-15 | -48.41 |
| 2026-01-14 | -49.40 |
| 2026-01-13 | -50.10 |
| 2026-01-12 | -52.58 |
| 2026-01-09 | -55.86 |
| 2026-01-08 | -56.16 |
| 2026-01-07 | -55.47 |
| 2026-01-06 | -54.27 |
| 2026-01-05 | -55.17 |
| 2026-01-02 | -54.17 |
| 2025-12-31 | -54.07 |